323 - Application Value of Whole-Process Individualized Intestinal Management in Radiotherapy for Gynecological Tumors: A Prospective Randomized Controlled Study
Presenter(s)
F. Bai1, J. Li2, L. Zhang3, L. Bo4, F. T. Yang5, L. L. Xu6, and L. Zhao7; 1Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, xi'an, Shaanxi, China, 2Department of Radiation Oncology,Xijing Hospital,Air Force Medical University CN, Xi’an, China, 3Department of Radiation Oncology,Xijing Hospital,Air Force Medical University CN, Xi'an, ShaanXi, China, 4Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University. Xi’an, China, Xi'an, Shanxi, China, 5Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University., xi'an, shaanxi, China, 6Department of Radiation Oncology,Xijing Hospital,Air Force Medical University CN, xi'an, ShaanXi, China, 7StateKey Laboratory of Holisticntegrative Managementof Gastrointestinal Cancersand Department of RadiationOncology,Xijing Hospital,Fourth Military MedicalUniversity, Xi'an, China
Purpose/Objective(s):
To investigate the clinical effect of whole-process individualized intestinal management in patients with gynecological tumors undergoing radiotherapy, and to evaluate its impacts on intestinal preparation compliance, radiotherapy-induced adverse reactions, quality of life and psychological status of the patients.Materials/Methods: A single-center, open-label, randomized controlled trial was conducted. A total of 212 patients with gynecological tumors who received radiotherapy in the First Affiliated Hospital of Air Force Military Medical University from January 2022 to December 2023 were enrolled and randomly divided into the experimental group and the control group at a ratio of 1:1, with 106 cases in each group. The control group was given routine intestinal preparation guidance, while the experimental group received whole-process individualized intestinal management, including comprehensive interventions such as dietary guidance, health education, psychological nursing, abdominal massage and telephone re-education before positioning. The Common Terminology Criteria for Adverse Events (CTCAE) V3.0 was used to evaluate radiotherapy-induced adverse reactions, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) was applied to assess quality of life, and the Hospital Anxiety and Depression Scale (HADS) was adopted to determine anxiety and depression status. Meanwhile, indicators such as intestinal preparation compliance and bladder filling consistency were recorded. Statistical analysis was performed using statistical software: measurement data were analyzed by t-test or rank sum test, and count data by ?² test. A P value < 0.05 was considered statistically significant.
Results:
The intestinal preparation compliance of the experimental group was significantly higher than that of the control group, and the incidence and severity of radiotherapy-related intestinal adverse reactions were significantly lower in the experimental group (P<0.05). The scores of all dimensions of the EORTC QLQ-C30 scale and the HADS anxiety and depression scores in the experimental group were significantly better than those in the control group (P<0.05), and the bladder filling consistency was also higher in the experimental group (P<0.05).Conclusion:
Whole-process individualized intestinal management can effectively improve the intestinal preparation compliance of patients with gynecological tumors undergoing radiotherapy, reduce radiotherapy-induced intestinal adverse reactions, improve patients' quality of life and psychological status, and enhance the accuracy of radiotherapy positioning, which is worthy of clinical promotion and application.